Safety Topics

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

*Due to the nature of post-marketing adverse event reports, some of the investigations remain ongoing and therefore may be subject to change. For more information, please see the FAQs.